Literature DB >> 23325836

Delivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD8(+) T-cell recall responses.

Liang Zhang1, Byram W Bridle, Lan Chen, Jonathan Pol, David Spaner, Jeanette E Boudreau, Allison Rosen, Jennifer D Bassett, Brian D Lichty, Jonathan L Bramson, Yonghong Wan.   

Abstract

Rapid boosting of memory CD8(+) T cells (TM) is essential in cancer immunotherapy and the control of certain infectious diseases. However, effector T cells (TE) are a barrier to booster vaccination because they can rapidly kill antigen-bearing antigen-presenting cells (APCs) before TM are engaged. We demonstrate that viral-vectored vaccines delivered by B cells elicit robust TM expansion in the presence of TE, enabling booster immunizations to bypass TE-mediated negative feedback regulation. Our data indicate that viral vector-loaded B cells home to the follicular regions in secondary lymphoid organs, which are anatomically separated from TE and in close proximity to TM. The B cells, however, do not serve as APCs in this area. Rather, classic CD11c(+) dendritic cells serve to stimulate the secondary CD8(+) T-cell response. Our data reveal that B cells represent a novel and readily accessible delivery system that can effectively engage secondary CD8(+) T-cell activation for prime-boost strategies.

Entities:  

Mesh:

Year:  2013        PMID: 23325836     DOI: 10.1182/blood-2012-06-438481

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

Review 1.  Trial watch: DNA-based vaccines for oncological indications.

Authors:  Stefano Pierini; Renzo Perales-Linares; Mireia Uribe-Herranz; Jonathan G Pol; Laurence Zitvogel; Guido Kroemer; Andrea Facciabene; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-11-20       Impact factor: 8.110

2.  Type I IFN blockade uncouples immunotherapy-induced antitumor immunity and autoimmune toxicity.

Authors:  Scott R Walsh; Donald Bastin; Lan Chen; Andrew Nguyen; Christopher J Storbeck; Charles Lefebvre; David Stojdl; Jonathan L Bramson; John C Bell; Yonghong Wan
Journal:  J Clin Invest       Date:  2018-12-18       Impact factor: 14.808

3.  Autophagy and proteasome interconnect to coordinate cross-presentation through MHC class I pathway in B cells.

Authors:  Vijayendra Dasari; Sweera Rehan; Siok-Keen Tey; Mark J Smyth; Corey Smith; Rajiv Khanna
Journal:  Immunol Cell Biol       Date:  2016-06-14       Impact factor: 5.126

4.  Combining dendritic cells and B cells for presentation of oxidised tumour antigens to CD8+ T cells.

Authors:  Melanie L Grant; Nicholas Shields; Silke Neumann; Katrin Kramer; Andrea Bonato; Christopher Jackson; Margaret A Baird; Sarah L Young
Journal:  Clin Transl Immunology       Date:  2017-07-07

Review 5.  Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies.

Authors:  Amelia Sadie Aitken; Dominic Guy Roy; Marie-Claude Bourgeois-Daigneault
Journal:  Biomedicines       Date:  2017-01-04

Review 6.  Attacking Postoperative Metastases using Perioperative Oncolytic Viruses and Viral Vaccines.

Authors:  Lee-Hwa Tai; Rebecca Auer
Journal:  Front Oncol       Date:  2014-08-12       Impact factor: 6.244

7.  Estradiol Enhances CD4+ T-Cell Anti-Viral Immunity by Priming Vaginal DCs to Induce Th17 Responses via an IL-1-Dependent Pathway.

Authors:  Varun C Anipindi; Puja Bagri; Kristy Roth; Sara E Dizzell; Philip V Nguyen; Christopher R Shaler; Derek K Chu; Rodrigo Jiménez-Saiz; Hong Liang; Stephanie Swift; Aisha Nazli; Jessica K Kafka; Jonathan Bramson; Zhou Xing; Manel Jordana; Yonghong Wan; Denis P Snider; Martin R Stampfli; Charu Kaushic
Journal:  PLoS Pathog       Date:  2016-05-05       Impact factor: 6.823

Review 8.  Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy.

Authors:  Boris Simovic; Scott R Walsh; Yonghong Wan
Journal:  Oncolytic Virother       Date:  2015-10-15

Review 9.  Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer.

Authors:  Dmitriy Zamarin; Jedd D Wolchok
Journal:  Mol Ther Oncolytics       Date:  2014-12-10       Impact factor: 7.200

10.  Chimeric antigen receptor-engineered T cells as oncolytic virus carriers.

Authors:  Heather VanSeggelen; Daniela Gm Tantalo; Arya Afsahi; Joanne A Hammill; Jonathan L Bramson
Journal:  Mol Ther Oncolytics       Date:  2015-09-09       Impact factor: 7.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.